Compare ACNT & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACNT | SPRO |
|---|---|---|
| Founded | 1945 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 118.8M | 136.7M |
| IPO Year | N/A | 2017 |
| Metric | ACNT | SPRO |
|---|---|---|
| Price | $15.21 | $2.33 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 84.6K | ★ 383.8K |
| Earning Date | 11-04-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $171,413,000.00 | $40,549,000.00 |
| Revenue This Year | $22.72 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $161.57 | ★ N/A |
| Revenue Growth | ★ 65.05 | N/A |
| 52 Week Low | $10.76 | $0.51 |
| 52 Week High | $15.69 | $3.22 |
| Indicator | ACNT | SPRO |
|---|---|---|
| Relative Strength Index (RSI) | 68.35 | 50.09 |
| Support Level | $14.74 | $2.26 |
| Resistance Level | $15.69 | $2.36 |
| Average True Range (ATR) | 0.59 | 0.10 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 76.54 | 62.50 |
Ascent Industries Co is a specialty chemicals platform focused on the development, production, and distribution of tailored, performance-driven chemical solutions. It has one reportable segment: Specialty Chemicals. The Specialty Chemicals segment includes the operating results of the Company's plants involved in the production of specialty chemicals and produces critical ingredients and process aids for the oil & gas, household, industrial and institutional (HII), personal care, coatings, adhesives, sealants and elastomers (CASE), pulp and paper, textile, automotive, agricultural, water treatment, construction and other industries.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.